- Tiziana Life Sciences said it had submitted an investigational new drug application to the US Food and Drug Administration.

It was submitted to initiate a Phase 1 clinical trial of enteric-coated capsules of Foralumab in healthy volunteers.

Foralumab was being developed for the treatment of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis and nonalcoholic fatty liver disease.

At 8:57am: [LON:TILS] Tiziana Life Sciences Plc share price was +0.5p at 43.5p

Story provided by